Reduced numbers of regulatory T cells in chronic heart failure seems not to be restored by cardiac resynchronization therapy

[1]  A. Mebazaa,et al.  Immunity and inflammation: the neglected key players in congenital heart disease? , 2021, Heart Failure Reviews.

[2]  G. Santulli,et al.  Glycation of ryanodine receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  Yuzhi Lu,et al.  Regulatory T Cells in Chronic Heart Failure , 2021, Frontiers in Immunology.

[4]  Hyunsu Kang.  Sample size determination and power analysis using the G*Power software , 2021, Journal of educational evaluation for health professions.

[5]  R. Dutton.  Inflammation After Surgical Trauma: Bleeding or Clotting? , 2020, Anesthesia and analgesia.

[6]  J. Hulot,et al.  Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling , 2020, Nature Communications.

[7]  Yuzhi Lu,et al.  A Unique Population of Regulatory T Cells in Heart Potentiates Cardiac Protection from Myocardial Infarction. , 2020, Circulation.

[8]  Yundai Chen,et al.  Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications , 2020, Journal of immunology research.

[9]  C. F. Ribeiro,et al.  Improvement in circulating endothelial progenitor cells pool after cardiac resynchronization therapy: increasing the list of benefits , 2020, Stem Cell Research & Therapy.

[10]  N. Xia,et al.  Pathologic T-cell response in ischaemic failing hearts elucidated by T-cell receptor sequencing and phenotypic characterization. , 2019, European heart journal.

[11]  G. Lombardi,et al.  Getting to the Heart of the Matter: The Role of Regulatory T-Cells (Tregs) in Cardiovascular Disease (CVD) and Atherosclerosis , 2019, Front. Immunol..

[12]  K. Stenmark,et al.  Role of Inflammatory Cell Subtypes in Heart Failure , 2019, Journal of immunology research.

[13]  Robert M. Blanton,et al.  T Cell recruitment to the heart: friendly guests or unwelcome visitors? , 2019, American journal of physiology. Heart and circulatory physiology.

[14]  J. Sluijter,et al.  Lymphocytic subsets play distinct roles in heart diseases , 2019, Theranostics.

[15]  S. Prabhu,et al.  Dysfunctional and Proinflammatory Regulatory T-Lymphocytes Are Essential for Adverse Cardiac Remodeling in Ischemic Cardiomyopathy , 2019, Circulation.

[16]  T. Ganz,et al.  Anemia of inflammation. , 2019, Blood.

[17]  E. Bianchini,et al.  Inflammation in deep vein thrombosis: a therapeutic target? , 2019, Hematology.

[18]  P. Laranjeira,et al.  Impact of cardiac resynchronization therapy on circulating IL-17 producing cells in patients with advanced heart failure , 2018, Journal of Interventional Cardiac Electrophysiology.

[19]  A. Abreu,et al.  Impact of cardiac resynchronization therapy on inflammatory biomarkers and cardiac remodeling: The paradox of functional and echocardiographic response. , 2018, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[20]  E. Mascha,et al.  Unadjusted Bivariate Two-Group Comparisons: When Simpler is Better , 2018, Anesthesia and analgesia.

[21]  K. Kamiński,et al.  Interleukin-6 signaling in patients with chronic heart failure treated with cardiac resynchronization therapy , 2016, Archives of medical science : AMS.

[22]  S. Chemtob,et al.  Sterile inflammation and pregnancy complications: a review. , 2016, Reproduction.

[23]  Xiaona Lu,et al.  Study on the effect and mechanism of the dysfunction of CD4(+) T cells in the disease process of chronic cardiac failure. , 2016, Asian Pacific journal of tropical medicine.

[24]  M. Radomski,et al.  Sepsis-associated thrombocytopenia. , 2016, Thrombosis research.

[25]  S. Lerakis,et al.  Lipid Interventions in Aortic Valvular Disease , 2015, The American journal of the medical sciences.

[26]  T. Mollnes,et al.  Effect of Cardiac Resynchronization Therapy on Inflammation in Congestive Heart Failure: A Review , 2015, Scandinavian journal of immunology.

[27]  S. Laradi,et al.  Transfusion et inflammation : hier – aujourd’hui – demain , 2015 .

[28]  X. Tu,et al.  Activated regulatory T-cells attenuate myocardial ischaemia/reperfusion injury through a CD39-dependent mechanism. , 2015, Clinical science.

[29]  Ryan A Frieler,et al.  Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. , 2015, Circulation.

[30]  F. Annunziato,et al.  The 3 major types of innate and adaptive cell-mediated effector immunity. , 2015, The Journal of allergy and clinical immunology.

[31]  P. Ponikowski,et al.  Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) – Polish population , 2015, Archives of medical science : AMS.

[32]  S. Laradi,et al.  [Blood transfusion and inflammation as of yesterday, today and tomorrow]. , 2015, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[33]  D. Dutka,et al.  Development of a multiparametric score to predict left ventricular remodelling and prognosis after cardiac resynchronization therapy , 2014, European journal of heart failure.

[34]  J. Lord,et al.  The systemic immune response to trauma: an overview of pathophysiology and treatment , 2014, The Lancet.

[35]  Z. Haque,et al.  Regulatory T cells are recruited in the infarcted mouse myocardium and may modulate fibroblast phenotype and function. , 2014, American journal of physiology. Heart and circulatory physiology.

[36]  S. Pedersen,et al.  Association between brain natriuretic peptide, markers of inflammation and the objective and subjective response to cardiac resynchronization therapy , 2014, Brain, Behavior, and Immunity.

[37]  G. Ertl,et al.  Foxp3+ CD4+ T Cells Improve Healing After Myocardial Infarction by Modulating Monocyte/Macrophage Differentiation , 2014, Circulation research.

[38]  H. Línková,et al.  Changes and Prognostic Impact of Apoptotic and Inflammatory Cytokines in Patients Treated with Cardiac Resynchronization Therapy , 2013, Cardiology.

[39]  M. Dorobanțu,et al.  Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects. , 2013, Clinical biochemistry.

[40]  L. Krishnan,et al.  Introduction to the immune system. , 2013, Methods in molecular biology.

[41]  A. Valado,et al.  Phenotypic and Functional Alterations on Inflammatory Peripheral Blood Cells After Acute Myocardial Infarction , 2012, Journal of Cardiovascular Translational Research.

[42]  Antony Vinh,et al.  Inflammation, Immunity, and Hypertension , 2011, Hypertension.

[43]  M. Isobe,et al.  Regulatory T lymphocytes attenuate myocardial infarction-induced ventricular remodeling in mice. , 2011, International heart journal.

[44]  A. Liston,et al.  Regulatory T Cells , 2011, Methods in Molecular Biology.

[45]  Jing Yuan,et al.  Regulatory T cells ameliorate cardiac remodeling after myocardial infarction , 2011, Basic Research in Cardiology.

[46]  Yun Zhang,et al.  The Th17/Treg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[47]  Jing Yuan,et al.  Defective Circulating CD4+CD25+Foxp3+CD127low Regulatory T-cells in Patients with Chronic Heart Failure , 2010, Cellular Physiology and Biochemistry.

[48]  M. Mehra,et al.  Chronic heart failure: contemporary diagnosis and management. , 2010, Mayo Clinic proceedings.

[49]  S. Pedreiro,et al.  Frequency and functional activity of Th17, Tc17 and other T-cell subsets in Systemic Lupus Erythematosus. , 2010, Cellular immunology.

[50]  Jianyi(Jay) Zhang,et al.  Heart failure management: the present and the future. , 2009, Antioxidants & redox signaling.

[51]  T. Strutt,et al.  Tc17, a Unique Subset of CD8 T Cells That Can Protect against Lethal Influenza Challenge1 , 2009, The Journal of Immunology.

[52]  P. Ponikowski,et al.  Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology , 2009, European journal of heart failure.

[53]  A. Michelucci,et al.  Effects of cardiac resynchronization therapy on systemic inflammation and neurohormonal pathways in heart failure. , 2009, Cardiology journal.

[54]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[55]  S. Raja,et al.  Impact of Off‐Pump Coronary Artery Bypass Surgery on Systemic Inflammation: Current Best Available Evidence , 2007, Journal of cardiac surgery.

[56]  Y. Nishimura,et al.  Relation between CD4+ T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 2007, The American journal of cardiology.

[57]  F. Sofi,et al.  Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy. , 2007, Journal of cardiac failure.

[58]  M. Montagnana,et al.  Inflammation and platelet activation in peripheral arterial occlusive disease. , 2007, The International journal of angiology : official publication of the International College of Angiology, Inc.

[59]  A. Banham.  Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. , 2006, Trends in immunology.

[60]  A. Feldman,et al.  Coxsackievirus B3 Induces T Regulatory Cells, Which Inhibit Cardiomyopathy in Tumor Necrosis Factor-α Transgenic Mice , 2006, Circulation research.

[61]  K. Lappegård,et al.  Anti‐Inflammatory Effect of Cardiac Resynchronization Therapy , 2006, Pacing and clinical electrophysiology : PACE.

[62]  G. Boriani,et al.  Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: Time courses and prediction of response , 2006, Peptides.

[63]  F. Ronchese,et al.  The phenotype of type 1 and type 2 CD8+ T cells activated in vitro is affected by culture conditions and correlates with effector activity , 2005, Immunology.

[64]  G. Torre-Amione.  Immune activation in chronic heart failure. , 2005, The American journal of cardiology.

[65]  S. Frøland,et al.  Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. , 2003, Cardiovascular research.

[66]  K. Kalantar-Zadeh,et al.  Inflammation and nutrition in renal insufficiency. , 2003, Advances in renal replacement therapy.

[67]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[68]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[69]  S. Frøland,et al.  Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. , 2002, Cardiovascular research.

[70]  M. Yamaoka-Tojo,et al.  Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. , 2002, Journal of cardiac failure.